exicuretx.com (XCUR): Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
This chart illustrates the market valuation of Exicure, Inc. (XCUR) on the GURU.Markets platform at 0.00, which correlates with an emergency revision of the development portfolio to combat trial stagnation. The business relies on unique spherical drug delivery structures that provide significant pricing power. Meanwhile, management is currently focused on asset preservation and identifying a survival strategy during a period of organizational change.
Analytical breakdowns for Exicure, Inc.
- stock price and consensus target price:
- stock exchange capitalization data:
- book value of equity indicators:
- debt and solvency information:
Total Debt to Capital Exicure, Inc.|XCUR - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Exicure|XCUR - Company Aggregate Debt|Debts to Book Capitalization Exicure, Inc.|XCUR - Company Long-Term Liabilities|Company Current Liabilities Exicure|Quick Liquidity Indicator exicuretx.com
- financial results and valuation multiples details:
XCUR - Company Profit|Projected Future Earnings Exicure, Inc.|XCUR - Price to Earnings Ratio|Projected Price to Earnings Exicure|XCUR - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Exicure, Inc.|XCUR - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Exicure|XCUR - Earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months exicuretx.com|XCUR - Earnings per share growth this year|Earnings growth forecast for next year Exicure, Inc.
Fundamental company valuation:Exicure Corp XCUR
The current EV/EBITDA multiple reflects the market value of Exicure, Inc. (XCUR) inclusive of debt relative to operating profit, which is critical for a biotechnology leader in SNA technologies. This indicator's trend compares actual exchange trades with earnings before interest, taxes, depreciation, and amortization, allowing for an assessment of the efficiency of multi-billion dollar R&D investments and the stability of the company's capitalization between financial reports.
Competitors of Exicure, Inc. (XCUR)
tempus.com - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Qiagen Corp QGEN|IONS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation RGEN (repligen.com)|RNA: EV/EBITDA Multiple|Company Value to EBITDA CRISPR Therapeutics Inc (CRSP)|Enterprise Value to EBITDA Ratio WGS|RARE: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple BEAM|Total Company Value to Operating Income Before Depreciation Ratio sarepta.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Twist Bioscience, Inc. TWST|TXG: Enterprise Value to Operating Income Before Depreciation|Intellia - EV/EBITDA Multiple|Stoke Corp (STOK) - Enterprise Value to EBITDA Ratio|BLFS (BioLife Solutions, Inc.) - Enterprise Value to EBITDA Ratio|WVE - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio MAZE|Enterprise Value to Operating Income Before Depreciation SION (Sionna Therapeutics, Inc.)|EV/EBITDA Multiple PRME|Enterprise Value to EBITDA Ratio Taysha Corp TSHA|uniQure N.V. - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple meiragtx.com MGTX|RGNX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation SLDB (Solid Biosciences Inc)|OCGN: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation PACB|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Benitec Biopharma Inc.|Enterprise Value to Operating Income Before Depreciation DSGN (designtx.com)|EV/EBITDA Multiple RCKT|EV/EBITDA Multiple 4DMT (FDMT)|EV/EBITDA Multiple LXEO (Lexeo Therapeutics, Inc.)|Korro Bio Inc. (KRRO) - Company Value to EBITDA|EDIT: Enterprise Value to EBITDA Ratio|SLN (silence-therapeutics.com) - Enterprise Value to Operating Income Before Depreciation|PRQR: EV/EBITDA Multiple|CDXS - Total Company Value to Operating Income Before Depreciation Ratio|SGMO (Sangamo) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Nautilus Biotechnology Inc (NAUT)|Enterprise Value to EBITDA Ratio MGX (Metagenomi, Inc.)|EV/EBITDA Multiple precisionbiosciences.com (DTIL)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Generation Bio GBIO|Business Value to Operating Income Before Depreciation BOLD|Celsion Corporation - EV/EBITDA Multiple|Company Value to EBITDA Phio Pharmaceuticals|MBIO (mustangbio.com) - Enterprise Value to EBITDA Ratio|TransCode Therapeutics, Inc. - Business Value to Operating Income Before Depreciation|BNGO (Bionano Genomics Inc.) - EV/EBITDA Multiple|Applied DNA Sciences Inc (APDN) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Bluebird Bio (BLUE)|immunoprecise.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple OMGA (Omega Therapeutics)|OMIC - Enterprise Value to EBITDA Ratio|RGLS: Enterprise Value to EBITDA Ratio|Total Company Value to Operating Income Before Depreciation Ratio Syros Pharmaceuticals Inc. SYRS|TBIO (Codex DNA) - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation TCON|UBX (Unity Biotechnology) - EV/EBITDA Multiple
